Search
trans NV-04
go.drugbank.com/drugs/DB05843Experimentaltrans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.
Brolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigational[L9089] Brolucizumab was granted FDA approval in October 2019.[L9089] … Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Romlusevimab
go.drugbank.com/drugs/DB16494InvestigationalRomlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.
Evans blue
go.drugbank.com/drugs/DB09361InvestigationalCategories: Compounds used in a research, industrial, or household settingParaoxon
go.drugbank.com/drugs/DB13495ExperimentalCategories: Compounds used in a research, industrial, or household settingMefenamic acid
go.drugbank.com/drugs/DB00784ApprovedIt is an inhibitor of cyclooxygenase.
Synonyms: N-2,3-xylylanthranilic acid, N-(2,3-xylyl)-2-aminobenzoic acid4-Hydroxytestosterone
go.drugbank.com/drugs/DB01485IllicitInvestigational[A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in … It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.
Rhodamine B
go.drugbank.com/drugs/DB16853ExperimentalCategories: Compounds used in a research, industrial, or household settingDelorazepam
go.drugbank.com/drugs/DB01511IllicitInvestigationalIn addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy. … It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam.
International brands: ENProducts: ENLX6171
go.drugbank.com/drugs/DB05180InvestigationalLX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia